Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Water-Electrolyte Imbalance

ClinicalTrials.gov lists 710 trials for Water-Electrolyte Imbalance or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 29.

MeSH D014883 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 17 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 54 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 76 Phase 4 Phase 4 89 Not applicable Not applicable 256 Observational Observational 196 Phase 1 Phase 1 17 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 54 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 76 Phase 4 Phase 4 89 Not applicable Not applicable 256 Observational Observational 196

Trials per phase (log scale)

18 of the 710 trials are tagged with Water-Electrolyte Imbalance itself; the rest are tagged with a narrower condition beneath it.

Get the Water-Electrolyte Imbalance report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Water-Electrolyte Imbalance trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 57

1993: 2 trials (Observational 1, Phase 2 1) 1997: 1 trials (Observational 1) 1999: 1 trials (Not applicable 1) 2000: 2 trials (Phase 3 2) 2001: 2 trials (Observational 1, Phase 2 1) 2002: 5 trials (Not applicable 2, Phase 4 1, Phase 3 1, Phase 2 1) 2003: 6 trials (Observational 1, Not applicable 2, Phase 3 2, Phase 2/3 1) 2004: 10 trials (Not applicable 4, Phase 3 3, Phase 2 3) 2005: 9 trials (Observational 1, Phase 4 4, Phase 3 2, Phase 2 1, Phase 1/2 1) 2006: 10 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 3, Phase 2 1) 2007: 16 trials (Observational 3, Not applicable 4, Phase 4 2, Phase 3 5, Phase 1/2 1, Phase 1 1) 2008: 27 trials (Observational 2, Not applicable 3, Phase 4 10, Phase 3 5, Phase 2/3 1, Phase 2 6) 2009: 25 trials (Observational 5, Not applicable 2, Phase 4 5, Phase 3 4, Phase 2 4, Phase 1 5) 2010: 31 trials (Observational 12, Not applicable 6, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1/2 2) 2011: 28 trials (Observational 11, Not applicable 8, Phase 4 2, Phase 3 2, Phase 2 5) 2012: 23 trials (Observational 8, Not applicable 5, Phase 4 6, Phase 3 2, Phase 2/3 1, Phase 1/2 1) 2013: 34 trials (Observational 9, Not applicable 14, Phase 4 3, Phase 3 6, Phase 2 1, Phase 1/2 1) 2014: 45 trials (Observational 13, Not applicable 17, Phase 4 7, Phase 3 5, Phase 2 2, Phase 1 1) 2015: 20 trials (Observational 8, Not applicable 7, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2016: 35 trials (Observational 7, Not applicable 15, Phase 4 6, Phase 3 2, Phase 2/3 3, Phase 2 1, Phase 1 1) 2017: 33 trials (Observational 7, Not applicable 13, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1 1) 2018: 27 trials (Observational 6, Not applicable 10, Phase 4 4, Phase 3 2, Phase 2 4, Phase 1 1) 2019: 38 trials (Observational 16, Not applicable 13, Phase 4 6, Phase 3 2, Phase 2 1) 2020: 33 trials (Observational 14, Not applicable 13, Phase 4 3, Phase 3 2, Phase 1 1) 2021: 57 trials (Observational 17, Not applicable 17, Phase 4 8, Phase 3 9, Phase 2 3, Phase 1/2 1, Phase 1 2) 2022: 42 trials (Observational 19, Not applicable 14, Phase 4 4, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 2023: 34 trials (Observational 7, Not applicable 19, Phase 4 1, Phase 3 2, Phase 2 3, Phase 1 2) 2024: 42 trials (Observational 10, Not applicable 26, Phase 4 2, Phase 3 2, Phase 2 2) 2025: 36 trials (Observational 8, Not applicable 19, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 30
2025 36
2024 42
2023 34
2022 42
2021 57
2020 33
2019 38
2018 27
2017 33

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 38 trials starting in 2026 and about 37 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 44 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 470 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Water-Electrolyte Imbalance trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 17
Phase 1/2 10
Phase 2 54
Phase 2/3 12
Phase 3 76
Phase 4 89
Not applicable 256
Observational 196

How many Water-Electrolyte Imbalance trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 28
Recruiting 50
Enrolling by invitation 3
Active, not recruiting 19
Completed 427

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Water-Electrolyte Imbalance trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 29
Cumberland Pharmaceuticals 9
Otsuka Pharmaceutical Development & Commercialization, Inc. 9
ZS Pharma, Inc. 8
Amgen 7

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Water-Electrolyte Imbalance? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Sodium Zirconium Cyclosilicate 26
Patiromer 14
Conivaptan 11
.spironolactone 9
Calcitriol 8

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tolvaptan IR 26
NaCl 0.9% NS 7
Empagliflozine 6
Low dose losartan 5
Paricalitol 5

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Water-Electrolyte Imbalance trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 344 31
Cardiac failure congestive 267 18
Renal failure acute 231 8
Hyperkalaemia 213 17
Acute myocardial infarction 145 15

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Water-Electrolyte Imbalance? (229)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Effect of the Chronic Kidney Disease-Peritoneal Dialysis (CKD-PD) App on Improvement of Overhydration Treatment in Patients on Peritoneal Dialysis: Randomized Controlled Trial. Journal of medical Internet research 2025 Yes
Evaluation of natriuresis-guided depletion after cardiac surgery: protocol for a single-centre, open-label, randomised controlled trial-the EASY-CS study. BMJ open 2025 Yes
Furosemide versus placebo for fluid overload in intensive care patients-The randomised GODIF trial second version: Statistical analysis plan. Acta anaesthesiologica Scandinavica 2024 Yes
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD. Journal of the American Society of Nephrology : JASN 2024 Yes
Electrolyte disorders related emergencies in children. BMC nephrology 2024 Yes

Showing 5 of 229 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages